Plain-English translation of NCT06023212 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing whether —a medication that helps blood clot and reduces bleeding—can lower the amount of blood loss during and after surgery to remove tumors from the spine in patients with advanced lung cancer. Right now, this type of spine surgery often causes heavy bleeding and serious complications. Researchers want to see if the medication can make surgery safer by reducing blood loss.
Surgery to remove spine tumors in lung cancer patients can cause severe bleeding and life-threatening complications. This trial exists to find out whether this medication can prevent excessive blood loss and improve surgical outcomes.
You likely qualify if…
You likely don't qualify if…
You will receive either the medication or a saline solution (salt water) as a placebo before your spine surgery begins, plus medicated or placebo-soaked gauze during wound closure. After surgery, you will receive three more injections of either the medication or saline over the next 24 hours. The research team will carefully track how much blood you lose during and after the operation to compare the two groups.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
China